Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Zentalis Pharmaceuticals, Inc. (ZNTL) had Consolidated Net Income/Loss of $-26.69M for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
-- |
|
$-26.69M |
|
-- |
|
-- |
|
$33.73M |
|
$-33.73M |
|
$7.04M |
|
$-26.69M |
|
$-26.69M |
|
$-26.69M |
|
$-26.69M |
|
|
Consolidated Net Income/Loss |
$-26.69M |
$-26.69M |
|
$-33.73M |
|
$-34.09M |
|
72.14M |
|
72.14M |
|
$-0.37 |
|
$-0.37 |
|
| Balance Sheet Financials | |
$288.30M |
|
$2.93M |
|
$38.95M |
|
$327.25M |
|
$37.17M |
|
-- |
|
$37.21M |
|
$74.38M |
|
$252.87M |
|
$252.87M |
|
$252.87M |
|
72.25M |
|
| Cash Flow Statement Financials | |
$-94.31M |
|
$99.17M |
|
$0.30M |
|
$36.53M |
|
$41.70M |
|
$5.17M |
|
$17.60M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
7.76 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-93.74M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-10.56% |
|
-10.56% |
|
-8.16% |
|
-10.56% |
|
$3.50 |
|
$-1.30 |
|
$-1.31 |
|